Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level.

[1]  Oh-Hyung Kwon,et al.  Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-κB and is associated with poor patient outcome. , 2012, Cancer letters.

[2]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[3]  Pierre Sonveaux,et al.  Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.

[4]  Oh-Hyung Kwon,et al.  Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer. , 2011, Biochemical and biophysical research communications.

[5]  Tae-Wook Kang,et al.  GENT: Gene Expression Database of Normal and Tumor Tissues , 2011, Cancer informatics.

[6]  B. Kefas,et al.  Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. , 2010, Neuro-oncology.

[7]  Yuquan Wei,et al.  Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice , 2010, Cancer science.

[8]  Y. Miki,et al.  Pim-1 controls NF-κB signalling by stabilizing RelA/p65 , 2010, Cell Death and Differentiation.

[9]  N. Tanaka,et al.  Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification , 2009, Proceedings of the National Academy of Sciences.

[10]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[11]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[12]  T. Kaisho,et al.  PDLIM2-mediated termination of transcription factor NF-κB activation by intranuclear sequestration and degradation of the p65 subunit , 2007, Nature Immunology.

[13]  O. Ilkayeva,et al.  Glycogen Synthase Kinase 3α and 3β Mediate a Glucose-Sensitive Antiapoptotic Signaling Pathway To Stabilize Mcl-1 , 2007, Molecular and Cellular Biology.

[14]  M. García-Carrasco,et al.  The transcription factor nuclear factor-kappa B and cancer. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  Elisabeth Naschberger,et al.  EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. , 2005, Blood.

[16]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[17]  Guobin Wang,et al.  Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. , 2004, World journal of gastroenterology.

[18]  B. Marinari,et al.  CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Eigenbrodt,et al.  The tumor metabolome. , 2003, Anticancer research.

[20]  Huasheng Lu,et al.  Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis* , 2002, The Journal of Biological Chemistry.

[21]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[22]  P. Vaupel,et al.  Pyruvate kinase type M2: a crossroad in the tumor metabolome , 2002, British Journal of Nutrition.

[23]  A Garg,et al.  Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.

[24]  John Calvin Reed,et al.  Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines , 2001, Oncogene.

[25]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[26]  E. Eigenbrodt,et al.  Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. , 1997, Anticancer research.